Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

TICE salvage chemotherapy is effective for treating germ-cell tumors with poor prognosis.

This study found that eribulin-based chemotherapy resulted in longer median progression-free and overall survival, with fewer side effects, for advanced triple-negative breast cancer patients compared to other chemotherapy options.

This review reports that the compound Cepharanthine shows promise as a cancer therapy by inducing cell death, arresting cell growth, inhibiting tumor progression, modulating key oncogenic pathways, and reversing multidrug resistance, suggesting its potential for further investigation in oncology.

This study reports that VP-16-213 (etoposide) shows significant therapeutic activity in several cancers including small cell bronchogenic carcinoma and certain leukemias, with hematologic toxicity being the primary side effect.

In this study involving women undergoing taxane-based chemotherapy, a twice-daily topical application of BPM31543 was well-tolerated and showed potential in reducing severe hair loss, prompting further investigation at higher doses.

This study reported that topical BPM31543 was safe and well-tolerated for patients on taxane-based chemotherapy, with some efficacy indicated in reducing hair loss at all dosages tested.

This study found that a mitoxantrone, vincristine, and prednisolone regimen effectively treated recurrent breast cancer with a 70% response rate, though it was associated with significant myelosuppression.

This study reported that VCP combination chemotherapy achieved a complete response in 53% of advanced non-Hodgkin's lymphoma patients, although more intensive treatment may be needed for improved outcomes.

The authors reported that electrochemotherapy and electroporation-based treatments, both with and without cytotoxic drugs, show promise as safer and more effective options for breast cancer treatment, including metastatic cases and palliative care, in vitro and in vivo.

This study found that photobiomodulation may accelerate hair regrowth one month after chemotherapy in breast cancer patients, but no significant differences were observed at two and three months post-therapy.

This study highlights a paradox where valproic acid, known for causing hair loss, may also promote hair growth when applied topically.

The authors concluded that capecitabine and high-dose toremifene may be an effective treatment option for patients unable to undergo anthracycline or taxane therapies, based on one woman's cancer management.

In this mouse study, applying a vasoconstrictor before chemotherapy did not create a leukemia sanctuary or significantly impact survival outcomes, suggesting it may not interfere with leukemia treatment.

This phase II trial found that BI 2536 demonstrated limited antitumor activity across five solid tumor types, with no confirmed objective responses observed.

In a neonatal rat model, this study found that topical CDK2 inhibitors reduced chemotherapy-induced hair loss in 33 to 50% of the animals, suggesting a potential strategy for preventing alopecia in cancer patients.

In this case report, researchers observed that the monoclonal antibody bevacizumab may worsen hypothyroidism in patients, as seen in a 60-year-old woman with metastatic duodenal carcinoma. The authors suggest that thyroid function should be monitored when using VEGF inhibitor therapies due to potential adverse effects.

In this study, researchers found that cepharanthine significantly inhibited the growth of non-small cell lung cancer cells by inducing apoptosis through ROS generation and altering multiple signaling pathways, suggesting potential as a novel lung cancer treatment.

This study suggests that combining bendamustine with tucidinostat may improve survival in patients with relapsed or refractory adult T-cell leukemia/lymphoma, highlighting its potential for clinical investigation.

This study reported a 74% overall response rate for a new combination chemotherapy of mitoxantrone, etoposide, and prednisolone in patients with relapsed or refractory Hodgkin's disease or non-Hodgkin's lymphoma.

This study found that vismodegib was effective in treating basal cell carcinoma, achieving complete remission in some patients; however, significant side effects often required careful management to prevent therapy suspension, which can lead to resistance.

This Phase 1 study reported that topical application of BPM31543 was safe and well-tolerated in patients receiving taxane-based chemotherapy, with some experiencing less than 50% hair loss, suggesting potential efficacy in reducing chemotherapy-induced alopecia, although no maximum tolerated dose was identified.

This study found that albumin-bound paclitaxel combined with nedaplatin shows promise as neoadjuvant therapy for esophageal squamous cell carcinoma, achieving a high complete response rate with manageable side effects.

This study found that vinblastine treatment rapidly increased platelet counts in childhood refractory immune thrombocytopenia, providing effective control of bleeding symptoms, although side effects like neuropathic pain were common and resolved with dose adjustments.

This study found that Cinobufacin combined with chemotherapy improved clinical outcomes in breast cancer patients and reduced certain side effects compared to chemotherapy alone.

The BAYONET trial is a phase II study designed to assess the efficacy and safety of combining encorafenib, binimetinib, and cetuximab for patients with BRAF V600E-mutant metastatic colorectal cancer that is resistant to encorafenib plus cetuximab; results are not yet reported.

This study observed that a combination of low-dose cyclophosphamide and vinorelbine appears safe and has promising antitumor activity in patients with metastatic breast cancer resistant to anthracyclines and taxanes, achieving a 44% objective response rate at 6 months with manageable toxicity levels.

In this phase II clinical study, combining anlotinib with standard platinum-based chemotherapy showed promising outcomes and prognosis in treating extensive small-cell lung cancer, with high disease control and response rates.

This Phase II study found that BAY 43-9006, given at 400 mg orally twice daily, led to stable disease in 30% and tumor reduction in 40% of renal cell carcinoma patients.

This study found that nearly all nurses caring for chemotherapy patients showed detectable levels of cyclophosphamide in their urine, indicating significant occupational exposure to this antineoplastic drug.

In this study, tebentafusp-tebn improved overall survival in patients with metastatic uveal melanoma compared to standard therapies, despite higher rates of significant adverse events.